Page 1 | Search Results | Hematology, ASH Education Program

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Scherber RM, Mesa RA. Managing myelofibrosis (MF) that “blasts” through: advancements in the treatment of relapsed/refractory and blast-phase MF. Hematology Am Soc Hematol Educ Program . 2018;2018:118-126.

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 630.

https://doi.org/10.1182/hematology.201900100

Published: 2019

Journal Articles

JAK2 (and other genes) be nimble with MPN diagnosis, prognosis, and therapy

Michele Ciboddo, Ann Mullally

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 110–117.

https://doi.org/10.1182/asheducation-2018.1.110

Published: 2018

Journal Articles

Managing myelofibrosis (MF) that “blasts” through: advancements in the treatment of relapsed/refractory and blast-phase MF

Robyn M. Scherber, Ruben A. Mesa

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 118–126.

https://doi.org/10.1182/asheducation-2018.1.118

Published: 2018

Journal Articles

Myeloproliferative neoplasms: from origins to outcomes

Jyoti Nangalia, Anthony R. Green

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 470–479.

https://doi.org/10.1182/asheducation-2017.1.470

Published: 2017

Journal Articles

What are the current treatment approaches for patients with polycythemia vera and essential thrombocythemia?

Alessandro M. Vannucchi, Paola Guglielmelli

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 480–488.

https://doi.org/10.1182/asheducation-2017.1.480

Published: 2017

Journal Articles

Current treatment algorithm for the management of patients with myelofibrosis, JAK inhibitors, and beyond

Claire N. Harrison, Donal P. McLornan

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 489–497.

https://doi.org/10.1182/asheducation-2017.1.489

Published: 2017

Journal Articles

Update from the latest WHO classification of MPNs: a user’s manual

Francesco Passamonti, Margherita Maffioli

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 534–542.

https://doi.org/10.1182/asheducation-2016.1.534

Published: 2016

Journal Articles

Myelofibrosis: to transplant or not to transplant?

Rebecca Devlin, Vikas Gupta

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 543–551.

https://doi.org/10.1182/asheducation-2016.1.543

Published: 2016

Journal Articles

Evidence for Janus kinase (JAK) inhibitors for the prevention of major morbid events in patients with myeloproliferative neoplasms (MPNs)

Naveen Pemmaraju, Ruben Mesa

Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 649–651.

https://doi.org/10.1182/asheducation-2015.1.649

Published: 2015

Journal Articles

Management of symptoms in polycythemia vera and essential thrombocythemia patients

Deepti Radia, Holly L. Geyer

Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 340–348.

https://doi.org/10.1182/asheducation-2015.1.340

Published: 2015

Journal Articles

Looking forward: novel therapeutic approaches in chronic and advanced phases of myelofibrosis

John Mascarenhas

Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 329–339.

https://doi.org/10.1182/asheducation-2015.1.329

Published: 2015

Journal Articles

Therapy for myeloproliferative neoplasms: when, which agent, and how?

Holly L. Geyer, Ruben A. Mesa

Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 277–286.

https://doi.org/10.1182/asheducation-2014.1.277

Published: 2014

Journal Articles

Management of MPN beyond JAK2

Claire N. Harrison, Natalia Curto Garcia

Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 348–354.

https://doi.org/10.1182/asheducation-2014.1.348

Published: 2014

Journal Articles

How does JAK2V617F contribute to the pathogenesis of myeloproliferative neoplasms?

Edwin Chen, Ann Mullally

Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 268–276.

https://doi.org/10.1182/asheducation-2014.1.268

Published: 2014

Journal Articles

JAK inhibition in the myeloproliferative neoplasms: lessons learned from the bench and bedside

Jason Gotlib

Hematology Am Soc Hematol Educ Program (2013) 2013 (1): 529–537.

https://doi.org/10.1182/asheducation-2013.1.529

Published: 2013

Journal Articles

Beyond JAK inhibitor therapy in myelofibrosis

Olatoyosi Odenike

Hematology Am Soc Hematol Educ Program (2013) 2013 (1): 545–552.

https://doi.org/10.1182/asheducation-2013.1.545

Published: 2013

Journal Articles

Small-molecule inhibitors in myeloproliferative neoplasms: are we aiming for the right targets?

Stefan N. Constantinescu, William Vainchenker

Hematology Am Soc Hematol Educ Program (2012) 2012 (1): 553–560.

https://doi.org/10.1182/asheducation.V2012.1.553.3800163

Published: 2012

Journal Articles

Management of Myelofibrosis

Alessandro M. Vannucchi

Hematology Am Soc Hematol Educ Program (2011) 2011 (1): 222–230.

https://doi.org/10.1182/asheducation-2011.1.222

Published: 2011

Journal Articles

Management of Essential Thrombocythemia

Francisco Cervantes

Hematology Am Soc Hematol Educ Program (2011) 2011 (1): 215–221.

https://doi.org/10.1182/asheducation-2011.1.215

Published: 2011

Journal Articles

Assessing New Therapies and Their Overall Impact in Myelofibrosis

Ruben A. Mesa

Hematology Am Soc Hematol Educ Program (2010) 2010 (1): 115–121.

https://doi.org/10.1182/asheducation-2010.1.115

Published: 2010

NARROW

Scherber RM, Mesa RA. Managing myelofibrosis (MF) that “blasts” through: advancements in the treatment of relapsed/refractory and blast-phase MF. Hematology Am Soc Hematol Educ Program . 2018;2018:118-126.

JAK2 (and other genes) be nimble with MPN diagnosis, prognosis, and therapy

Managing myelofibrosis (MF) that “blasts” through: advancements in the treatment of relapsed/refractory and blast-phase MF

Myeloproliferative neoplasms: from origins to outcomes

What are the current treatment approaches for patients with polycythemia vera and essential thrombocythemia?

Current treatment algorithm for the management of patients with myelofibrosis, JAK inhibitors, and beyond

Update from the latest WHO classification of MPNs: a user’s manual

Myelofibrosis: to transplant or not to transplant?

Evidence for Janus kinase (JAK) inhibitors for the prevention of major morbid events in patients with myeloproliferative neoplasms (MPNs)

Management of symptoms in polycythemia vera and essential thrombocythemia patients

Looking forward: novel therapeutic approaches in chronic and advanced phases of myelofibrosis

Therapy for myeloproliferative neoplasms: when, which agent, and how?

Management of MPN beyond JAK2

How does JAK2V617F contribute to the pathogenesis of myeloproliferative neoplasms?

JAK inhibition in the myeloproliferative neoplasms: lessons learned from the bench and bedside

Beyond JAK inhibitor therapy in myelofibrosis

Small-molecule inhibitors in myeloproliferative neoplasms: are we aiming for the right targets?

Management of Myelofibrosis

Management of Essential Thrombocythemia

Assessing New Therapies and Their Overall Impact in Myelofibrosis

ASH Publications

American Society of Hematology

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only